Abstract
Purpose
The purpose of this study was to determine whether the presence of diabetes mellitus (DM) influences the incidence and severity of peripheral sensory neuropathy (PSN) in patients using taxane therapy.
Methods
A retrospective single-center analysis was conducted: Patients with PSN at baseline were excluded. The incidence of PSN was evaluated retrospectively in patient subgroups who received taxane arm and taxane-plus-platinum-agents combination arm with or without known DM at baseline.
Results
Three hundred seventy-four patients were enrolled in this study, 81 (21.6 %) of patients had DM at baseline. The incidence of grade 1 PSN (non-DM/DM) in patients receiving taxane-based chemotherapy was 33.4/25.9 % and more than grade 2 PSN (non-DM/DM) was 15/34.6 %. The rate of neuropathy of non-diabetic patients was 48.8 %, while the rate of diabetic patients was 52.8 and 75 % in DM duration below 5 years and above 5 years group, respectively.
Conclusions
This retrospective analysis indicates that taxane-based therapy in DM patients whose disease duration is above 5 years appears to affect the incidence and severity of PSN without known baseline neuropathy. The probability of PSN with taxane-based therapy was similar in DM duration below 5 years and non-DM patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapyinduced peripheral neuropathy. Semin Oncol 33:15–49 6
Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90:377–387
Hagiwara H, Sunada Y (2004) Mechanism of taxane neurotoxicity. Breast Cancer 11:82–85
Hamid HS, Mervak CM, Münch AE, Robell NJ, Hayes JM, Porzio MT et al (2014) Hyperglycemia- and neuropathy-induced changes in mitochondria within sensory nerves. nn Clin Transl Neurol 1:799–812
Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63:1549–1563
Edgardo R, Mary C (2015) Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 75(4):659–70
Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247–1259
Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP (2008) Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 66:218–228
Peters CM, Jimenez-Andrade JM, Jonas BM, Sevcik MA, Koewler NJ, Ghilardi JR, Wong GY, Manthy PW (2007) Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized bymacrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 203:42–54
Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P et al (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858–1867
Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P et al (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15:1517–1526
Chaudhry V, Chaudhry M, Crawford TO, Simmons-O’Brien E, Griffin JW (2003) Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60:337–340
Miltenburg NC, Boogerd W (2014) Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 40:872–882
Eckhoff L, Knoop AS, Jensen MB, Ejlertsen B, Ewertz M (2013) Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat 142:109–118
Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125:767–774
Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubulestabilizing agents. J Clin Oncol 24:1633–1642
Argyriou AA, Polychronopoulos P, Koutras A, Xiros N, Petsas T, Argyriou K, Kalofonos HP, Choroni E (2007) Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care 16:231–237
Amir A, Jaipaul S, SatyanR (2014) Pathogenesis of painful diabetic Neuropathy.Pain Res Treat:412041
Partanen J, Niskanen L, Lehtinen J, Mervaale E, Siitonen O, Uusitupa M (1995) Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 33:89–94
Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V et al (2012) Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane containing therapy for operable breast cancer. J Clin Oncol 30:3051–3057
Conflict of interest
The authors do not have any conflict of interest or financial disclosures.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kus, T., Aktas, G., Kalender, M.E. et al. Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study. Support Care Cancer 24, 1175–1179 (2016). https://doi.org/10.1007/s00520-015-2898-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-015-2898-z